Data are expressed as mean scores; error bars indicate 95% CI.
aP < .001
bP = .001
aP = .02.
eMethods. Implementation Facilitation–Formative Evaluation
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Hawk KF, D’Onofrio G, Chawarski MC, et al. Barriers and Facilitators to Clinician Readiness to Provide Emergency Department–Initiated Buprenorphine. JAMA Netw Open. 2020;3(5):e204561. doi:10.1001/jamanetworkopen.2020.4561
What are the key barriers and facilitators for clinician initiation of buprenorphine in the ED with referral for the treatment of opioid use disorder?
A mixed-methods evaluation of 268 attending physicians, resident physicians, and advanced practice clinicians in academic emergency departments found that 9 of 258 (3.5%) reported completion of Drug Addiction Treatment Act of 2000 training, and 56 of 268 (20.9%) had high levels of readiness to prescribe buprenorphine in the emergency department. Key barriers included lack of training and experience in treating opioid use disorder, concerns about ability to link to ongoing care, and competing needs for time and resources in a busy emergency department.
Although few emergency department clinicians in this study had high levels of readiness to initiate buprenorphine with referral for ongoing treatment, many expressed a willingness to learn with sufficient support, indicating the importance of clinician and system-level changes.
Treatment of opioid use disorder (OUD) with buprenorphine decreases opioid use and prevents morbidity and mortality. Emergency departments (EDs) are an important setting for buprenorphine initiation for patients with untreated OUD; however, readiness varies among ED clinicians.
To characterize barriers and facilitators of readiness to initiate buprenorphine for the treatment of OUD in the ED and identify opportunities to promote readiness across multiple clinician types.
Design, Setting, and Participants
Using data collected from April 1, 2018, to January 11, 2019, this mixed-methods formative evaluation grounded in the Promoting Action on Research Implementation in Health Services framework included 4 geographically diverse academic EDs. Attending physicians (n = 113), residents (n = 107), and advanced practice clinicians (APCs) (n = 48) completed surveys electronically distributed to all ED clinicians (n = 396). A subset of participants (n = 74) also participated in 1 of 11 focus group discussions. Data were analyzed from June 1, 2018, to February 22, 2020.
Main Outcomes and Measures
Clinician readiness to initiate buprenorphine and provide referral for ongoing treatment for patients with OUD treated in the ED was assessed using a visual analog scale. Responders (268 of 396 [67.7%]) were dichotomized as less ready (scores 0-6) or most ready (scores 7-10). An ED-adapted Organizational Readiness to Change Assessment (ORCA) and 11 focus groups were used to assess ratings and perspectives on evidence and context-related factors to promote ED-initiated buprenorphine with referral for ongoing treatment, respectively.
Among the 268 survey respondents (153 of 260 were men [58.8%], with a mean [SD] of 7.1 [9.8] years since completing formal training), 56 (20.9%) indicated readiness to initiate buprenorphine for ED patients with OUD. Nine of 258 (3.5%) reported Drug Addiction Treatment Act of 2000 training completion. Compared with those who were less ready, clinicians who were most ready to initiate buprenorphine had higher mean scores across all ORCA Evidence subscales (3.50 [95% CI, 3.35-3.65] to 4.33 [95% CI, 4.13-4.53] vs 3.11 [95% CI, 3.03-3.20] to 3.60 [95% CI, 3.49-3.70]; P < .001) and on the Slack Resources of the ORCA Context subscales (3.32 [95% CI, 3.08-3.55] vs 3.0 [95% CI, 2.87-3.12]; P = .02). Barriers to ED-initiated buprenorphine included lack of training and experience in treating OUD with buprenorphine, concerns about ability to link to ongoing care, and competing needs and priorities for ED time and resources. Facilitators to ED-initiated buprenorphine included receiving education and training, development of local departmental protocols, and receiving feedback on patient experiences and gaps in quality of care.
Conclusions and Relevance
Only a few ED clinicians had a high level of readiness to initiate buprenorphine; however, many expressed a willingness to learn with sufficient supports. Efforts to promote adoption of ED-initiated buprenorphine will require clinician and system-level changes.
In 2018, an estimated 2.0 million individuals in the United States had an opioid use disorder (OUD).1,2 Treatment with methadone or buprenorphine can mitigate adverse consequences and decrease mortality.3-7 Despite the strong evidence and clinical guidelines supporting use of these medications,8-10 as many as 80% of patients do not receive such potentially life-saving treatments.7,11
To address this treatment gap, the emergency department (ED) has emerged as an important location to identify patients with OUD and initiate buprenorphine with referral for ongoing treatment.12 Buprenorphine is a safe, effective OUD treatment that rapidly relieves withdrawal, may be dispensed by any licensed clinician in an ED, and unlike methadone, may be prescribed to outpatients for the treatment of OUD by any clinician who has completed approved training and received a Drug Addiction Treatment Act of 2000 (DATA 2000) waiver.8,13 Furthermore, previous studies14,15 demonstrated that when patients with OUD receive ED-initiated buprenorphine treatment with referral to ongoing care, the process promotes addiction treatment engagement and is cost-effective. Despite these data, adoption of ED-initiated buprenorphine nationwide has been limited.11,16,17 Thus, to inform future implementation efforts to promote ED-initiated buprenorphine with referral for ongoing treatment, we conducted a mixed-methods formative evaluation involving attending physicians, resident physicians, and advanced practice clinicians (APCs), including physician assistants and nurse practitioners, in 4 geographically disparate EDs across the United States.
A mixed-methods formative evaluation was conducted in the context of the ongoing Project ED Health,18,19 a study funded by the National Institute on Drug Abuse Center for the Clinical Trials Network in 4 geographically diverse EDs through January 2021. The study, a hybrid type III effectiveness-implementation trial,20 was designed to evaluate the effect of implementation facilitation21 vs a standard educational dissemination strategy on ED-initiated buprenorphine treatment.18 The present study was approved by the Western Institutional Review Board. The participants in this baseline evaluation of Project ED Health provided verbal informed consent.
The study approach was guided by the Promoting Action on Research Implementation in Health Services (PARiHS) framework. This framework is often used to understand how the interplay between perspectives on the evidence of the target evidence-based practice interacts with the context for delivering that practice and the facilitation strategy.22-24 Our quantitative approach was consistent with the American Association for Public Opinion Research guidelines as outlined in the Internet Surveys of Specifically Named Persons,25 and our qualitative approach adhered to the Consolidated Criteria for Reporting Qualitative Research (COREQ) reporting guideline.26
Project ED Health is being conducted in 4 academic, urban EDs in Baltimore, Maryland (annual visit volume, >70 000), New York, New York (annual visit volume, >90 000), Cincinnati, Ohio (annual visit volume, >75 000), and Seattle, Washington (annual visit volume, >60 000).18 Clinicians who were potential ED-based buprenorphine prescribers, including attending physicians, residents, and APCs (inclusive of physician assistants and nurse practitioners), and who had been employed at the respective EDs for at least 6 months before the study onset (n = 396) were invited to participate. Of those, 268 (67.7%) provided a response to the readiness question included in the online survey. Among the 396 clinicians invited to take the survey, 74 prescribers, including 37 attending physicians, 25 residents, and 12 APCs, participated in 4 faculty, 4 resident, and 3 APC focus groups.18 All focus group participants provided verbal informed consent.
The mixed-methods formative evaluation included quantitative and qualitative assessments informed by the PARiHS framework.23,27 Data collection for the present analysis occurred from April 1, 2018, through January 11, 2019, after a single Grand Rounds on ED-initiated buprenorphine by a lead study investigator (G.D.) and before any further study-related implementation efforts.
The quantitative assessment included a web-based, anonymous survey that collected self-reported data on demographic characteristics, training, and experiences with ED-initiated buprenorphine; ratings on the Evidence and Context subscales of the ED-adapted Organizational Readiness to Change Assessment (ORCA) (eMethods in the Supplement); and a visual analog scale using a readiness ruler that asked: “On a scale from 0 to 10, how ready are you to provide ED-initiated buprenorphine with referral for ongoing MAT [medication for addiction treatment] for the treatment of opioid use disorder, where 0 equals ‘not ready at all’ and 10 equals ‘totally ready?’”28
The ED-adapted ORCA assesses perspectives on evidence and context for ED-initiated buprenorphine with referral for ongoing treatment.18 The Evidence scale includes 4 subscales: Staff Discord (ie, perspectives on evidence among the respondent and their colleagues), Research Evidence, Clinical Practice Experience, and Patient Needs.29 Responses were collected on a 5-point Likert scale (1 indicates strongly disagree; 2, disagree; 3, neither agree nor disagree; 4, agree; and 5, strongly agree). The Context scale contains 5 subscales: Leadership Culture, Staff Culture (ie, staff organizational culture), Leadership Practice, Evaluation Accountability, and Opinion Leader Culture. An additional item assesses resources available to support practice change (Slack Resources).30 Responses were collected on a 5-point Likert scale (1 indicates very infrequently; 2, infrequently; 3, neither frequently nor infrequently; 4, frequently; and 5, very frequently). Answer choices “don’t know” and “not applicable” were also included for both scales. Subsequently, responses “don’t know” and “not applicable” were recoded as neither agree nor disagree or neither frequently nor infrequently, and subscale scores for the Evidence and Context domains were computed.
Qualitative data collection occurred through focus groups in a nonclinical space, with an a priori plan to have 1 faculty, resident, and APC focus group per site consistent with the number of focus groups typically required to achieve thematic saturation.31 Participants were volunteers invited through in-person and electronic communications. Refusals were not tracked. No participant dropped out during the focus group meetings. The focus group facilitators included authors (K.F.H., G.D., P.G.O., D.A.F., and E.J.E.) who identified themselves to the group as physician researchers trained in addiction medicine, emergency medicine, and/or internal medicine. A previously published focus group guide included grand tour questions with follow-up probes designed to elicit perspectives on prior experiences with treating OUD; understanding of the evidence supporting use of ED-initiated buprenorphine with referral for ongoing treatment; contextual factors related to ED-initiated buprenorphine with referral for ongoing treatment, including administrative and leadership support; and resources needed to implement this practice.18,32 All focus groups were digitally recorded and transcribed.
Survey data were analyzed from March 7, 2019, to February 22, 2020. Descriptive statistics were used to characterize participant characteristics. After a review of the distributional properties of responses to the readiness ruler question, participants in the bottom 4 quintiles (scores 0-6) were categorized as less ready, and participants in the top quintile (scores 7-10) were categorized as most ready. The 2 groups were then compared on their characteristics, their DATA 2000 waiver training status, and the ORCA subscales in an exploratory fashion. No a priori hypotheses were formulated. The statistical significance of differences between the 2 readiness level groups on their characteristics and the DATA 2000 waiver training status were evaluated using the Pearson χ2 test or the Fisher exact test (when the cell counts were less than 5). The difference in the years since completing clinical training was evaluated using the independent samples t test. The between-group differences on the ORCA subscales were evaluated using a multivariate analysis of variance with the readiness level (less ready vs most ready) as the between-group factor and including the site and clinician type (attending, resident, or APC) as covariate terms in the general linear multivariate model. The significance levels of the observed between-group differences were assessed using the F test statistic. A sensitivity analysis to compare the patterns of between-group differences on the ORCA subscales where the “don’t know” and “not applicable” responses were excluded and where they were recoded as neither agree nor disagree or neither frequently nor infrequently before computing the scores on the ORCA subscales was also conducted. Statistical analyses were performed using SPSS, version 24 (IBM Corporation). Two-tailed P < .05 indicated statistical significance.
Informed by the PARiHS framework, we used an inductive process of iterative coding to identify ideas and themes that was interpolated with conduction of focus groups.33 Three members of the investigative team (K.F.H., E.C., Jr, and E.J.E.) independently reviewed 7 transcripts line by line to develop and refine the codebook and reach consensus on codes and reached thematic saturation.31 An audit trail was maintained. One investigator (E.J.E.) then applied these codes consistently to all transcripts, using Atlas.ti software (ATLAS.ti Scientific Software Development) to facilitate data organization and retrieval. Themes were then generated based on coded quotations through discussion with the research team within the PARiHS framework.
Data were collected using a sequential explanatory strategy,34 with quantitative data collection preceding focus groups at each site. We used qualitative data to contextualize quantitative findings and triangulate the collected data.20
Of the 268 of 396 clinicians (67.7%) who completed the readiness ruler, 113 (42.2%) were attending physicians, 107 (39.9%) were residents, and 48 (17.9%) were APCs (Table 1). The majority of participants were male (153 of 260 were men [58.8%] and 107 of 260 were women [41.2%]) and white (205 of 240 [85.4%]). Nine of 258 participants (3.5%) reported having completed DATA 2000 training, including 5 attending physicians, 3 residents, and 1 APC. High readiness to initiate buprenorphine in the ED was endorsed by 56 participants overall (20.9%), including 24 of 113 attending physicians (21.2%), 26 of 107 residents (24.3%), and 6 of 48 APCs (12.5%).
Completion of DATA 2000 training was associated with higher levels of readiness for ED-initiated buprenorphine prescribing with referral for ongoing treatment (5 of 9 [55.6%]) compared with no DATA 2000 training (49 of 249 [19.7%]; χ2 = 6.756; P = .02). In addition, clinicians with higher levels of readiness to initiate buprenorphine with referral for ongoing treatment had significantly higher mean scores on all ORCA Evidence subscales than clinicians with lower levels of readiness, including Staff Discord (4.33 [95% CI, 4.13- 4.53] vs 3.60 [95% CI, 3.49-3.70]; P < .001), Research Evidence (3.67 [95% CI, 3.52-3.82] vs 3.38 [95% CI, 3.30-3.46]; P = .001), Clinical Practice Experience (3.80 [95% CI, 3.64-3.97] vs 3.32 [95% CI, 3.24-3.40]; P < .001), and Patient Needs (3.50 [95% CI: 3.35-3.65] vs 3.11 [95% CI, 3.03-3.20]; P < .001) (Figure 1). In a sensitivity analysis, the overall pattern of the between-group differences on the means of all subscales as well as the pattern of the corresponding statistical significance levels closely overlapped with the notable change of the Patient Needs subscale that was no longer statistically significant. Those most ready compared with less ready had the following mean scores on the Context subscales: Leadership Culture (3.62 [95% CI, 3.38-3.85] vs 3.75 [95% CI, 3.62-3.87]; P = .34), Staff Culture (3.97 [95% CI, 3.77-4.12] vs 3.98 [95% CI, 3.88-4.09]; P = .91), Leadership Practice (3.87 [95% CI, 3.63-4.11] vs 3.81 [95% CI, 3.68-3.94]: P = .67), Evaluation Accountability (3.62 [95% CI, 3.38-3.85] vs 3.65 [95% CI, 3.52-3.77]; P = .83), Opinion Leader Culture (4.05 [95% CI, 3.84-4.25] vs 3.87 [95% CI, 3.76-3.98]; P = .13), and Slack Resources (3.32 [95% CI, 3.08-3.55] vs 3.0 [95% CI, 2.87-3.12]; P = .02) (Figure 2).
Themes with representative quotations are organized by PARiHS domains of Evidence and Context. Factors associated with readiness for ED-initiated buprenorphine treatment are identified in Table 2.
Lack of training or personal experience initiating buprenorphine in the ED and absence of clear department protocols were identified as barriers to initiating buprenorphine with referral for treatment in the ED. Variability across clinician types in readiness to use buprenorphine was widespread. Key facilitators included widespread resident and APC enthusiasm to obtain training and implement practice change as well as a broad desire to improve outcomes for patients with OUD treated in the ED.
Mixed levels of knowledge and awareness of evidence supporting the initiation of buprenorphine with referral for ongoing treatment in the ED were evident, as were differences in the readiness to implement practice change across prescriber type. Although several individual attending physicians expressed enthusiasm, residents and APCs were more enthusiastic about learning how to initiate buprenorphine in the ED, although they still highlighted the need for clear support from departmental leadership and the development of local protocols and clinical guidelines to facilitate their ability to implement practice change.
With the exception of a few local champions, a vague understanding of the concept of ED-initiated buprenorphine was common. Some prescribers expressed concern that their patient population may be too medically or socially complex, but nearly all expressed a desire to learn more about the evidence supporting the use of buprenorphine, with the highest level of notable enthusiasm coming from residents and APCs.
Despite acknowledgment of a high prevalence of OUD among their patients, limited formal training on the treatment of OUD, including buprenorphine, was widely noted by participants. Specifically, participants believed themselves to be underprepared to identify patients appropriate for buprenorphine initiation and expressed lack of clear understanding of the regulations and laws guiding buprenorphine prescribing. Although the need for training was recognized, the requirement for DATA 2000 waiver training was perceived as a barrier. This contrasted with a recognition of the inadequacy of the traditional approach to OUD treatment with “handing out a pamphlet” and some early clinician experiences with dispensing buprenorphine in the ED to enhance overall readiness for adopting ED-initiated buprenorphine.
Conflicting perceptions about the scope of emergency care and the perceived role of the ED in initiating treatment for OUD were recurrent contextual barriers to initiating buprenorphine in the ED. Key facilitators include leadership support, leveraging reliance on protocols to improve care, quality improvement with audit and feedback, and the availability of multidisciplinary support resources.
Across clinician types, the need for a commitment from departmental leadership to support practice change was recognized. Residents and APCs highlighted the importance of leadership support in the educational as well as administrative sphere as a key component needed to facilitate practice change. One perceived important effect of leadership commitment was the dedication of resources to develop and implement local protocols and care pathways to facilitate practice change; development and implementation of a clinical protocol was consistently perceived as a necessary step to facilitate adoption of ED-initiated buprenorphine. Clinicians at each site reported examples of other successfully implemented ED protocols with clinical decision support that yielded streamlined and standardized care across clinicians. Residents and APCs noted that the existence of protocols would serve as helpful leverage when working with attendings who had not yet integrated the use of buprenorphine into their practices.
Clinicians varied in their perspectives on whether they believed that it was appropriate to initiate buprenorphine in the ED for patients with OUD as part of routine care. On one hand, some prescribers believed that it was more appropriate to prioritize care of patients with higher illness acuity over management of a chronic disease. On the other hand, some clinicians recognized that the ED offered an opportunity to initiate care that may not be provided otherwise. Similarly, although many clinicians were concerned about how much time initiating buprenorphine in the ED would take, others recognized that once fluent, this practice change may enhance ED flow, particularly if interdisciplinary support resources are used.
Uncertainty about whether the patient will be able to access and reliably attend follow-up appointments was one of the most commonly cited clinician concerns about initiating buprenorphine in the ED. Clinicians noted that receiving feedback about successful follow-up treatment of patients who experienced ED-initiated buprenorphine would enhance practice change and enhance readiness to initiate buprenorphine with referral for ongoing treatment in the ED.
Although experience with initiating buprenorphine in the ED across sites was limited, many clinicians favorably described the presence of early adopters of ED-initiated buprenorphine in their EDs (primarily attending physicians) who were working to influence practice change. The presence of multiple hospital and city-wide task forces to actively support the expansion of access to OUD treatment was noted.
A key contextual factor shared across sites and prescriber types was the identified need of multidisciplinary support to identify and educate patients and to facilitate follow-up logistics. Although specific requests varied among an addiction consultation team, peer navigators, nursing screening and assessments, or social work support, the request for support was universal.
To our knowledge, this study is the first to apply mixed methods to characterize factors associated with adoption of ED-initiated buprenorphine with referral for ongoing treatment from the perspectives of a diverse set of potential prescribers practicing in different regions of the United States. Our study reveals several key findings. Of 258 ED clinicians who responded, only 56 (20.9%) rated their readiness to initiate buprenorphine as 7 or more on a visual analog scale. Barriers to adoption of ED-initiated buprenorphine include a lack of formal training, limitations on time, limited knowledge of local treatment resources, absence of local protocols and referral networks, and perception or culture that this falls outside the scope and practice of emergency medicine. Facilitators include provision of education and training, establishment of protocols, and enhanced communication across different stakeholder groups. Together, these data are critical for guiding future implementation efforts to ensure that more patients with OUD receive potentially life-saving treatment with buprenorphine when seen in the ED.
Higher levels of readiness for prescribing buprenorphine in the ED were associated with higher scores on all ORCA Evidence subscales, whereas on the Context subscales, only higher Slack Resources subscale scores were associated with higher levels of readiness for ED-initiated buprenorphine with referral for ongoing treatment. As supported by the sensitivity analysis, the overall pattern of these between-group differences and the corresponding statistical significance levels were closely overlapping when the “don’t know” and “not applicable” ORCA responses were excluded and when they were recoded as neither agree nor disagree or neither frequently nor infrequently.
Despite strong endorsement of ED-initiated buprenorphine with referral for outpatient follow-up by the American College of Emergency Physicians, the American College of Medical Toxicology, and the National Institute on Drug Abuse, little has been published to date on ED clinician perspectives on initiating buprenorphine with referral for ongoing treatment in the ED.10,13,14,16,35,36 Consistent with our findings, 1 cross-sectional survey of 82 ED physicians within 1 health system also found that most participants were not prepared to initiate buprenorphine in the ED.37 A behavioral analysis approach to evaluating the effect of a campaign to increase DATA 2000 training completion among emergency physicians identified key barriers of absent social norms, the hassle of obtaining a waiver, and lack of salience in treating OUD in the ED.17 The need for a DATA 2000 waiver was identified as a barrier to initiating buprenorphine in the ED in our study as well, although there was some indication that an oversimplified view of the waiver as the main barrier may eclipse other areas of clinician resistance or factors slowing implementation by providing an easy answer for why clinicians do not view initiating buprenorphine as in their scope of practice.
Collectively, our study highlights several key strategies that may be useful for promoting adoption of ED-initiated buprenorphine. First, clinicians expressed the most interest in adopting practice change if they thought that it would improve patient outcomes. Second, we identified unique enthusiasm among residents and the potential for “teaching up,” in which practice change (eg, point of care ultrasonography) is driven by the delivery of new knowledge in medical and graduate curriculums, generating students, residents, and recent graduates with unique expertise to share with more established clinicians who want to keep up with evolving or novel clinical practices.38 Third, consistent with other ED-based quality improvement initiatives (care of sepsis and ST-elevation myocardial infarction), feedback on the number of patients with OUD who had treatment initiated in the ED and linked to ongoing care, coupled with individual success stories, could be powerful motivators to enhance practice change. Fourth, the importance of protocols cannot be overstated. They signify leadership and multistakeholder engagement and provide clear clinical evidence and guidelines about the goals of ED care of patients with OUD. Last, ED clinicians expressed a need for training, in addition to resources and personnel to support identification of patients who are appropriate for initiation of buprenorphine and to enhance treatment motivation and facilitate successful transitions of care.
Our study has some limitations. First, our findings may be subject to selection bias, recall bias, and social desirability bias owing to the conduct of the focus groups by study authors, including the previous grand rounds speaker. Two authors (K.F.H. and E.J.E.) facilitated focus groups and were part of the coding team, although potential effects of this dual role were mitigated by having each focus group include at least 1 facilitator not involved in the analysis and a member of the coding team (E.C. Jr) who did not conduct any focus groups. Across sites, research assistants purposively recruited participants based on clinical scheduling and existing meetings unrelated to our study to include a variety of perspectives on ED-initiated buprenorphine rather than those self-selecting to participate. Survey participation was deidentified, with some clinical and professional characteristics but no names, so direct correlation of survey data with focus group data was not possible. Second, our findings may not be generalizable to rural or community-based EDs. Third, perspectives and practices are rapidly evolving across these EDs, given the ongoing opioid epidemic, whereas the study findings are based on assessments at 1 time per site.
This study’s findings suggest that opportunities to promote readiness for ED-initiated buprenorphine with referral for ongoing treatment will need to address perspectives on the evidence and ED context for implementation. Specific opportunities to promote practice change vary across emergency clinician type. Future implementation strategies should consider these factors and tailor interventions accordingly for attending physicians, residents, and APCs.
Accepted for Publication: February 28, 2020.
Published: May 11, 2020. doi:10.1001/jamanetworkopen.2020.4561
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Hawk KF et al. JAMA Network Open.
Corresponding Author: Kathryn F. Hawk, MD, Department of Emergency Medicine, Yale School of Medicine, 464 Congress Ave, Ste 260, New Haven, CT 06519 (firstname.lastname@example.org).
Author Contributions: Drs Hawk and Chawarski had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Hawk, D’Onofrio, Chawarski, O’Connor, Martel, Pantalon, Fiellin, Edelman.
Acquisition, analysis, or interpretation of data: Hawk, D’Onofrio, Chawarski, O’Connor, Cowan, Lyons, Richardson, Rothman, Whiteside, Owens, Coupet, Pantalon, Curry, Fiellin, Edelman.
Drafting of the manuscript: Hawk, Chawarski, O’Connor, Martel, Pantalon, Edelman.
Critical revision of the manuscript for important intellectual content: Hawk, D’Onofrio, Chawarski, O’Connor, Cowan, Lyons, Richardson, Rothman, Whiteside, Owens, Coupet, Pantalon, Curry, Fiellin, Edelman.
Statistical analysis: Hawk, Chawarski, Curry.
Obtained funding: D’Onofrio, Chawarski, Owens, Pantalon, Fiellin.
Administrative, technical, or material support: Cowan, Lyons, Richardson, Rothman, Whiteside, Owens, Martel, Coupet, Pantalon, Fiellin.
Supervision: D’Onofrio, Lyons, Rothman, Owens, Pantalon, Fiellin.
Conflict of Interest Disclosures: Dr Hawk reported receiving grants from the National Institute on Drug Abuse (NIDA)/National Institutes of Health (NIH) during the conduct of this study. Dr D’Onofrio reported receiving grants from the NIDA/NIH, during the conduct of the study. Dr Chawarski reported receiving grants from the NIDA/NIH during the conduct of the study. Dr Cowan reported receiving grants from the NIDA/NIH during the conduct of the study. Dr Lyons reported receiving grants from the NIDA/NIH during the conduct of the study. Dr Richardson reported receiving grants from the NIDA/NIH during the conduct of the study. Dr Rothman reported receiving grants from the NIDA/NIH during the conduct of the study. Dr Whiteside reported receiving grants from the NIDA Center for the Clinical Trials Network (CTN) and the NIDA/NIH during the conduct of the study. Ms Owens reported receiving grants from the NIDA/NIH during the conduct of the study. Ms Martel reported receiving grants from the NIDA/NIH during the conduct of the study. Dr Pantalon reported receiving personal fees from Center for Progressive Recovery outside the submitted work and funding from the NIDA/NIH during the conduct of the study. Dr Fiellin reported receiving grants from the NIDA/NIH during the conduct of the study and honoraria from Springer Nature, Boston Medical Center, University of New South Wales, University of Alabama, Birmingham, US Department of Justice, Tufts University, American Society of Addiction Medicine, American Academy of Addiction Psychiatry, Boston University, and University of Kentucky. Dr Edelman reported receiving grants from the NIDA/NIH during the conduct of the study. No other disclosures were reported.
Funding/Support: This study was supported by grant 5UG1DA015831-15 (CTN-0069) from the NIDA/NIH and grant K12 2K12 DA033312-06 from the NIDA/NIH (Dr Coupet).
Role of the Funder/Sponsor: The NIDA collaborated in the design and conduct of the study and reviewed and provided comments for consideration in drafts of the manuscript. They were not involved in the data collection, management, or analysis and did not have final approval of the manuscript for submission.
Additional Contributions: Christian Helfrich, MPH, PhD, Health Services University of Washington School of Public Health, provided guidance and assistance in the modification and scoring of the Organizational Readiness to Change Assessment for use in the emergency department on the topic of initiating buprenorphine treatment. He was not compensated for this work.
Create a personal account or sign in to: